RECRUITING Phase 2 ClinicalTrials.gov

De-escalation Study for Stage IIa/IIb < 3 cm Seminoma

Sponsor: Centre Leon Berard • ClinicalTrials.gov ID: NCT05529251

Registry updated: 2026-09-15

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study. Patients with stage IIa/IIb \< 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of Etoposide Cisplatine (EP) chemotherapy. Patients with negative week-3 PET-scan after the EP cycle, will be randomized (1:1 ratio, stratification according to the disease stage (stage IIa versus IIb seminoma)) to receive either radiotherapy (RT) boost on lymph nodes or 1 cycle of carboplatin AUC7 chemotherapy. Patients with positive week-3 PET-scan will received 3 additional cycles of EP chemotherapy. In parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.

Interventions

Radiotherapy boost (Radiation)
Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week : * 20 Gy if no more disease is visible (node \< 1 cm in large diameter) * 24 Gy for nodes \<= 2 cm * 30 Gy for nodes \> 2 cm
Carboplatin AUC7 (Drug)
Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
3 cycles of EP (Drug)
3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice

Eligibility criteria

Inclusion criteria : 1. Age ≥ 18 years on the day of signing informed consent. 2. Primary testicular seminomatous germ cell tumor. 3. Stage IIa/IIb \< 3 cm in largest diameter seminoma, histologically proved after orchiectomy. 4. Confirmation of a progressive disease (positive PET scan or increase of lymph nodes size by two successive CT scan). 5. Good prognosis according to IGCCCG and LDH \< 2.5 x Upper Limit of Normal (ULN). 6. Normal alpha-fetoprotein (AFP) before and after orchiectomy. 7. No prior treatment with radiotherapy or chemotherapy. 8. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2. 9. Adequate bone-marrow, hepatic, and renal functions with: * Neutrophils ≥ 1.5 x Giga/l, platelets ≥ 100 x Giga/l, * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 1,5 x ULN, * Serum creatinine \< 140 µmol/l OR calculated clearance \> 60 ml/min (using either Cockcroft-Gault formula or Modification of Diet in Renal Disease (MDRD) for \> 65 years old), * Total bilirubin ≤ ULN (if \> ULN, direct bilirubin ≤ ULN). 10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. 11. Accepting to use effective contraceptive measures or abstain from heterosexual activity, for the course of the study and through 12 months after the last dose of chemotherapy or being surgically sterile. All patients should seek advice regarding cryoconservation of sperm prior treatment initiation because of the possibility of infertility 12. Affiliation to a health insurance. 13. Signed and dated informed consent. Non-exclusion criteria : 1. Extra-retroperitoneal metastasis on Computed tomography scan (CT scan). 2. Infection by Human Immunodeficiency Virus (HIV), or active infection with the Hepatitis B or C virus. 3. History, within 2 years, of cancer other than seminoma, except for treated skin cancer (basal cell). 4. Uncontrolled or severe cardiovascular pathology. 5. Uncontrolled or severe hepatic pathology. 6. Patient deprived of liberty or requiring tutorship or curatorship. 7. Psychological, physical, sociological, or geographical conditions that would limit compliance with study protocol requirements (at the investigator's discretion). 8. Participation to another clinical trial, except for supportive care trials.

Conditions

Seminoma Stage II

Locations

CHU Besançon — Besançon, France
CHU Bordeaux — Bordeaux, France
Centre François Baclesse — Caen, France
Centre Jean Perrin — Clermont-Ferrand, France
Centre Oscar Lambret — Lille, France
CHU de Limoges — Limoges, France
Centre Leon Bérard — Lyon, France
Institut Paoli Calmettes — Marseille, France
Centre Antoine Lacassagne — Nice, France
Hôpital Saint Louis — Paris, France
ICO René Gauducheau — Saint-Herblain, France
Hôpital Foch — Suresnes, France
Institut Universitaire de Cancer de Toulouse (IUCT-O) — Toulouse, France
Institut de Cancérologie de Lorraine — Vandœuvre-lès-Nancy, France
Institut Gustave Roussy — Villejuif, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment